Truist Securities Starts Dianthus Therapeutics (DNTH) at Buy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Truist Securities Starts Dianthus Therapeutics (DNTH) at Buy

Guggenheim on Dianthus (DNTH) and Leads BioLabs Deal: 'We view this as a well-structured deal'

October 16, 2025 9:56 AM EDT

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $100.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

The analyst comments "Today, DNTH announced an exclusive global (ex-Greater China) license agreement with Leads Biolabs (HKG: 9887) for DNTH-212, a first-in-class bifunctional BDCA2 and BAFF/APRIL inhibitor, designed to modulate both innate and... More